End-of-day quote
Shenzhen S.E.
06:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
12.9
CNY
|
-1.90%
|
|
-3.44%
|
-45.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,731
|
21,269
|
20,829
|
15,754
|
14,881
|
7,991
|
-
|
-
|
Enterprise Value (EV)
1 |
13,731
|
21,269
|
22,701
|
17,255
|
15,810
|
9,264
|
10,753
|
10,471
|
P/E ratio
|
39.5
x
|
26.6
x
|
18
x
|
10.9
x
|
48.4
x
|
12
x
|
8.9
x
|
7.72
x
|
Yield
|
0.58%
|
0.38%
|
0.4%
|
0.8%
|
0.25%
|
0.9%
|
1.45%
|
1.23%
|
Capitalization / Revenue
|
1.62
x
|
2
x
|
1.59
x
|
0.78
x
|
1.11
x
|
0.56
x
|
0.49
x
|
0.46
x
|
EV / Revenue
|
1.62
x
|
2
x
|
1.74
x
|
0.85
x
|
1.18
x
|
0.64
x
|
0.66
x
|
0.6
x
|
EV / EBITDA
|
12.7
x
|
12.6
x
|
10.1
x
|
4.93
x
|
11.3
x
|
4.41
x
|
4.16
x
|
3.89
x
|
EV / FCF
|
160
x
|
19.5
x
|
30.1
x
|
24.4
x
|
12.7
x
|
59.4
x
|
14.9
x
|
9.07
x
|
FCF Yield
|
0.63%
|
5.12%
|
3.32%
|
4.09%
|
7.85%
|
1.68%
|
6.7%
|
11%
|
Price to Book
|
3.45
x
|
4.53
x
|
3.57
x
|
2.12
x
|
1.97
x
|
0.98
x
|
0.89
x
|
0.83
x
|
Nbr of stocks (in thousands)
|
620,458
|
620,458
|
620,458
|
626,898
|
624,979
|
619,450
|
-
|
-
|
Reference price
2 |
22.13
|
34.28
|
33.57
|
25.13
|
23.81
|
12.90
|
12.90
|
12.90
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,453
|
10,649
|
13,083
|
20,282
|
13,408
|
14,381
|
16,224
|
17,377
|
EBITDA
1 |
1,079
|
1,686
|
2,255
|
3,502
|
1,396
|
2,101
|
2,587
|
2,691
|
EBIT
1 |
774.6
|
1,320
|
1,838
|
2,823
|
842.2
|
1,436
|
1,795
|
2,182
|
Operating Margin
|
9.16%
|
12.4%
|
14.05%
|
13.92%
|
6.28%
|
9.99%
|
11.06%
|
12.55%
|
Earnings before Tax (EBT)
1 |
771.2
|
1,317
|
1,791
|
2,544
|
798.3
|
1,400
|
1,754
|
2,026
|
Net income
1 |
347.3
|
802.9
|
1,163
|
1,434
|
307.5
|
674.1
|
909.2
|
1,045
|
Net margin
|
4.11%
|
7.54%
|
8.89%
|
7.07%
|
2.29%
|
4.69%
|
5.6%
|
6.02%
|
EPS
2 |
0.5600
|
1.290
|
1.863
|
2.298
|
0.4918
|
1.076
|
1.450
|
1.672
|
Free Cash Flow
1 |
85.95
|
1,090
|
753
|
706.4
|
1,242
|
156
|
720
|
1,155
|
FCF margin
|
1.02%
|
10.23%
|
5.76%
|
3.48%
|
9.26%
|
1.08%
|
4.44%
|
6.65%
|
FCF Conversion (EBITDA)
|
7.97%
|
64.64%
|
33.4%
|
20.17%
|
88.93%
|
7.43%
|
27.83%
|
42.92%
|
FCF Conversion (Net income)
|
24.75%
|
135.72%
|
64.75%
|
49.25%
|
403.83%
|
23.14%
|
79.19%
|
110.5%
|
Dividend per Share
2 |
0.1280
|
0.1300
|
0.1350
|
0.2000
|
0.0600
|
0.1162
|
0.1867
|
0.1585
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3,744
|
4,649
|
6,104
|
4,876
|
4,653
|
3,232
|
3,610
|
3,450
|
3,116
|
2,973
|
3,662
|
3,624
|
3,437
|
8,482
|
4,172
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
60.03
|
1,082
|
1,501
|
814.1
|
-575
|
-
|
419.2
|
252.7
|
-190.2
|
102.9
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
1.6%
|
23.28%
|
24.6%
|
16.69%
|
-12.36%
|
-
|
11.61%
|
7.32%
|
-6.1%
|
3.46%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
23.17
|
-
|
-
|
-
|
1,192
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.78%
|
-
|
-
|
-
|
14.05%
|
-
|
EPS
2 |
-0.0900
|
1.209
|
1.810
|
0.8800
|
-1.600
|
0.2554
|
0.4600
|
0.1300
|
-0.3600
|
0.0371
|
0.4250
|
0.3400
|
0.0300
|
0.5600
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/15/22
|
4/26/22
|
8/26/22
|
10/26/22
|
4/12/23
|
4/26/23
|
8/30/23
|
10/27/23
|
4/19/24
|
4/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
1,872
|
1,501
|
929
|
1,274
|
2,762
|
2,480
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.8302
x
|
0.4288
x
|
0.6655
x
|
0.6062
x
|
1.068
x
|
0.9218
x
|
Free Cash Flow
1 |
85.9
|
1,090
|
753
|
706
|
1,242
|
156
|
720
|
1,155
|
ROE (net income / shareholders' equity)
|
9.04%
|
18.6%
|
22.1%
|
21.7%
|
4.1%
|
9.21%
|
10.2%
|
10.2%
|
ROA (Net income/ Total Assets)
|
3.24%
|
6.94%
|
8.31%
|
7.83%
|
-
|
4.08%
|
4.72%
|
5.15%
|
Assets
1 |
10,709
|
11,575
|
13,996
|
18,325
|
-
|
16,521
|
19,263
|
20,297
|
Book Value Per Share
2 |
6.420
|
7.570
|
9.420
|
11.90
|
12.10
|
13.20
|
14.50
|
15.50
|
Cash Flow per Share
2 |
0.7800
|
2.490
|
2.120
|
2.620
|
3.060
|
2.700
|
2.490
|
3.100
|
Capex
1 |
397
|
457
|
565
|
933
|
680
|
561
|
546
|
513
|
Capex / Sales
|
4.7%
|
4.3%
|
4.32%
|
4.6%
|
5.07%
|
3.9%
|
3.37%
|
2.95%
|
Announcement Date
|
2/28/20
|
4/9/21
|
4/15/22
|
4/12/23
|
4/19/24
|
-
|
-
|
-
|
Last Close Price
12.9
CNY Average target price
22.37
CNY Spread / Average Target +73.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.82% | 1.12B | | -22.94% | 7.77B | | +76.76% | 4.51B | | +6.87% | 2.76B | | -2.63% | 2.67B | | -49.74% | 2.09B | | -18.60% | 1.72B | | -19.40% | 1.49B | | +18.29% | 1.22B | | +20.68% | 1.05B |
Medical & Diagnostic Laboratories
|